North America Depression Therapeutics Market is expected to foster due to patent expiry of blockbuster drugs.

Download Sample

Published Date: June 2023

Antidepressants are used to treat a wide range of mental disorder, which includes anxiety, depression and other major depressive disorder. Rising prevalence of mental disorders such as depression and anxiety is expected to foster the growth of North America depression therapeutics market. According to Anxiety & Depression Association of America (ADAA), major depressive disorder is the leading cause of disability in the U.S., among people aged between 15 years and 44.3 years. The North America Depression Therapeutics Market accounted for US$ XX million in 2020 and is estimated to be US$ XX million by 2030 and is anticipated to register a CAGR of XX%.

The report " North America Depression Therapeutics Market, By Drug Type (Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), and Others (Serotonin Modulators, Tricyclic & Tetracyclic Antidepressant and, Atypical Antidepressant)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Country (U.S. and Canada) - Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

June 2021, Sage Therapeutics and Biogen announced positive results from a pivotal Phase III trial of their novel antidepressant zuranolone. Zuranolone has demonstrated rapid antidepressant effects, and one course of zuranolone treatment is only 14 days long. This would be particularly advantageous for patients and could alter the way MDD is treated, shifting the focus to episodic treatment instead of maintenance treatment.
On July 2021, -Lyndra Therapeutics, a clinical-stage biotechnology company working to make daily pills a thing of the past announced the positive outcome of an end-of-phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) providing a clear path to approval for Lyndra’s Weekly Risperidone (LYN-005), the company’s lead product candidate for once-weekly treatment of schizophrenia.

Analyst View:

Continuous demand for antidepressant medications, from generic manufactures is expected due to rising prevalence of mental disorders such as depression, bipolar disorder and anxiety. Further, the key players are also involved to manufacture and develop innovative generic counterparts of branded products. Depression therapeutics market is also expected to foster due to patent expiry of several potential blockbuster drugs.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “North America Depression Therapeutics Market, By Drug Type (Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), and Others (Serotonin Modulators, Tricyclic & Tetracyclic Antidepressant and, Atypical Antidepressant)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Country (U.S. and Canada) - Market Trends, Analysis, and Forecast till 2030”

Key Market Insights from the report:

The North America Depression Therapeutics Market accounted for US$ XX million in 2020 and is estimated to be US$ XX million by 2029 and is anticipated to register a CAGR of XX%. The North America Depression Therapeutics Market is segmented based on the type, distribution channel, and region.

By Drug Type, the North America Depression Therapeutics Market is segmented into Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), and Others (Serotonin Modulators, Tricyclic & Tetracyclic Antidepressant and, Atypical Antidepressant.
By distribution channel, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy.
By region, the North America Depression Therapeutics Market is segmented into U.S. and Canada.

Competitive Landscape:

The key players operating in the North America Depression Therapeutics Market include Pfizer, Inc., Eli Lilly and Company, AstraZeneca Plc, Allergan Plc, GlaxoSmithKline Plc, Intellipharmaceutics International, Inc., Takeda Pharmaceutical Company Limited, H.Lundbeck A/S, and, Apotex, Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Some Important Points Answered in this Market Report Are Given Below:

Explains an overview of the product portfolio, including product development, planning, and positioning
Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
Detailed analysis of the market revenue over the forecasted period.
Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
Study on the segments that are anticipated to dominate the market.
Study on the regional analysis that is expected to register the highest growth over the forecast period